Brooke Kania, DO

National Cancer Institute

Latest Content

Clinical trial image showing Broke Kania, DO, discussing the Talaporo-3 study on cancer treatment with Talazoparib and Enzalutamide for HRR-mutated mCSPC.

Conferences

06/06/2026

TALAPRO-3: A Major rPFS Win in HRR-Mutated mCSPC, But Which Patients Benefit Most?

Brooke Kania, DO

Advanced molecular testing and targeted therapies for prostate cancer research and treatment.

Prostate Cancer

03/16/2026

ASCO GU 2026: Experts Highlight Key Updates in Prostate Cancer

Brooke Kania, DOSindhuja Kadambi, MD, MS